Physician profile
Patrick Pierre
NPI 1487809729
$6,938.39
in general payments reported to CMS, 2019-2025
19 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.77 · 2020: $5,000 · 2021: $15.22 · 2022: $257 · 2023: $611 · 2024: $684 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,000.00 | 2020 | |
| Abbott Laboratories | $373.96 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $273.63 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.33 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $168.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $144.81 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $103.52 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $97.05 | 2022-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $90.75 | 2024-2025 | |
| Inspire Medical Systems, INC. | $67.50 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $62.65 | 2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $62.44 | 2023 | Keveyis |
| Medtronic, INC. | $60.32 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Pfizer INC. | $56.49 | 2023-2025 | |
| Dexcom, INC. | $39.44 | 2024-2025 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.94 | 2024-2025 | |
| Astellas Pharma US INC | $22.87 | 2023 | Veozah |
| Corium, LLC | $20.32 | 2023 | Adlarity |
| Phathom Pharmaceuticals, INC. | $5.97 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.